Product
LY2157299
4 clinical trials
4 indications
Indication
GliomaIndication
GlioblastomaIndication
Prostate CancerIndication
Rectal AdenocarcinomaClinical trial
Phase 1 Dose-Escalation Study of LY2157299 Monotherapy and in Combination With Lomustine in Patients With Recurrent Malignant GliomaStatus: Active (not recruiting), Estimated PCD: 2012-05-22
Clinical trial
A Phase 2 Study of LY2157299 Monohydrate Monotherapy or LY2157299 Monohydrate Plus Lomustine Therapy Compared to Lomustine Monotherapy in Patients With Recurrent GlioblastomaStatus: Active (not recruiting), Estimated PCD: 2014-07-26
Clinical trial
Overcoming Drug Resistance in Metastatic Castration-resistant Prostate Cancer With Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: a Randomized Multi-site Phase II StudyStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Clinical trial
Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal AdenocarcinomaStatus: Active (not recruiting), Estimated PCD: 2025-12-01